Federal Circuit Confirms Patentability Of Epilepsy Treatment
Mealey's (February 4, 2019, 11:04 AM EST) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Feb. 1 rejected a challenge to an adverse inter partes review (IPR) by the Patent Trial and Appeal Board, agreeing...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login